JP7663237B2 - がん免疫療法のためのｃｄ２００ａｒリガンド - Google Patents

がん免疫療法のためのｃｄ２００ａｒリガンド Download PDF

Info

Publication number
JP7663237B2
JP7663237B2 JP2021540174A JP2021540174A JP7663237B2 JP 7663237 B2 JP7663237 B2 JP 7663237B2 JP 2021540174 A JP2021540174 A JP 2021540174A JP 2021540174 A JP2021540174 A JP 2021540174A JP 7663237 B2 JP7663237 B2 JP 7663237B2
Authority
JP
Japan
Prior art keywords
cd200ar
cells
tumor
composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517226A (ja
JP2022517226A5 (enExample
Inventor
マイケル オーリン，
Original Assignee
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リージェンツ オブ ザ ユニバーシティ オブ ミネソタ filed Critical リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Publication of JP2022517226A publication Critical patent/JP2022517226A/ja
Publication of JP2022517226A5 publication Critical patent/JP2022517226A5/ja
Application granted granted Critical
Publication of JP7663237B2 publication Critical patent/JP7663237B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2021540174A 2019-01-14 2020-01-13 がん免疫療法のためのｃｄ２００ａｒリガンド Active JP7663237B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962792311P 2019-01-14 2019-01-14
US62/792,311 2019-01-14
PCT/US2020/013349 WO2020150149A1 (en) 2019-01-14 2020-01-13 Cd200ar ligands for cancer immunotherapy

Publications (3)

Publication Number Publication Date
JP2022517226A JP2022517226A (ja) 2022-03-07
JP2022517226A5 JP2022517226A5 (enExample) 2023-01-05
JP7663237B2 true JP7663237B2 (ja) 2025-04-16

Family

ID=69467802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540174A Active JP7663237B2 (ja) 2019-01-14 2020-01-13 がん免疫療法のためのｃｄ２００ａｒリガンド

Country Status (5)

Country Link
US (2) US12414983B2 (enExample)
EP (1) EP3911357B1 (enExample)
JP (1) JP7663237B2 (enExample)
AU (1) AU2020208192A1 (enExample)
WO (1) WO2020150149A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024259195A1 (en) * 2023-06-16 2024-12-19 Elias Animal Health Use of cd200ar-l for enhancing adoptive t-cell therapy
WO2025259866A2 (en) * 2024-06-14 2025-12-18 Elias Animal Health Combination of chemotherapy, cancer cell vaccine and adoptive cell therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326028A1 (en) 2015-11-03 2018-11-15 Regents Of The University Of Minnesota Cd200 inhibitors and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
PT1032662E (pt) 1997-11-07 2006-07-31 Trillium Therapeutics Inc Metodos e composicoes para imunomodulacao.
AU2002223338B2 (en) 2000-11-22 2007-06-07 Trillium Therapeutics Inc. Truncated CD200
EP2463305B1 (en) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
JP2010534243A (ja) 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２００に対する抗体および免疫応答への使用
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
SG10201913573UA (en) * 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326028A1 (en) 2015-11-03 2018-11-15 Regents Of The University Of Minnesota Cd200 inhibitors and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Leukemia，2015年，Vol.29，pp.1952-1954，doi:10.1038/leu.2015.62

Also Published As

Publication number Publication date
AU2020208192A1 (en) 2021-08-05
US20260158109A1 (en) 2026-06-11
JP2022517226A (ja) 2022-03-07
WO2020150149A1 (en) 2020-07-23
CA3126156A1 (en) 2020-07-23
EP3911357A1 (en) 2021-11-24
US20220088134A1 (en) 2022-03-24
US12414983B2 (en) 2025-09-16
EP3911357B1 (en) 2026-04-29

Similar Documents

Publication Publication Date Title
CN101835792B (zh) Foxm1肽和包含foxm1肽的药剂
EP2186889B1 (en) Cdca1 peptide and pharmaceutical agent comprising the same
JP2018538265A (ja) 癌を治療するための方法及び組成物
US9884098B2 (en) Multivalent breast cancer vaccine
CN116916960A (zh) PPAR-delta抑制剂联合免疫治疗药物在制备抗肿瘤药物中的应用
JP2020532553A (ja) 組み合わせがん療法
EP3911357B1 (en) Cd200ar ligands for cancer immunotherapy
Zeng et al. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2, 3-dioxygenase inhibitor 1-methyl tryptophan
EP4427761A1 (en) Vaccine against pancreatic cancer, and medical use thereof
US20220370558A1 (en) Combination cancer immunotherapy
JP6902185B2 (ja) Ｃｄ２００阻害剤及びその使用方法
JP6649953B2 (ja) 免疫療法による治療および組成物
CA3126156C (en) Cd200ar ligands for cancer immunotherapy
CA3037253A1 (en) Methods of treating tim-3 elevation
US20250381248A1 (en) Methods of treating a tumor
WO2020216963A1 (en) Personalized immunotherapy for treatment of cancer
EP4215214A1 (en) Cancer therapeutic agent, immunostimulant and screening method for anticancer substance
US20230201341A1 (en) Tlr3 and tlr9 agonists as vaccine adjuvants for anti-cancer dna vaccines
US20250134976A1 (en) Compositions for inducing intratumoral immune triads and uses thereof
WO2018088933A1 (en) Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
Caffrey et al. IgE-based therapeutic combination enhances antitumor response in preclinical models of pancreatic cancer.
HK40114150A (en) Immunostimulatory mrna compositions and uses thereof
HK1141312B (en) Cdca1 peptide and pharmaceutical agent comprising the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250328

R150 Certificate of patent or registration of utility model

Ref document number: 7663237

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150